BioVie Inc. (NASDAQ:BIVI – Get Rating) was the target of a significant decline in short interest during the month of May. As of May 31st, there was short interest totalling 78,200 shares, a decline of 35.7% from the May 15th total of 121,700 shares. Currently, 1.5% of the company’s shares are sold short. Based on […]
Brokerages expect BioVie Inc. (NASDAQ:BIVI – Get Rating) to post ($0.42) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for BioVie’s earnings. BioVie reported earnings of ($10.18) per share in the same quarter last year, which would suggest a positive year over year growth rate […]
BioVie (NASDAQ:BIVI – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Thursday, Zacks.com reports. The brokerage presently has a $2.75 price objective on the stock. Zacks Investment Research‘s price objective would indicate a potential upside of 8.27% from the company’s […]
BioVie (NASDAQ:BIVI – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, Zacks.com reports. According to Zacks, “BioVie Inc. engages in developing drug therapies for liver disease. The company’s product candidate includes BIV201, which are in clinical stage. BioVie […]
BioVie (NASDAQ:BIVI – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Thursday, Zacks.com reports. The firm currently has a $3.25 price objective on the stock. Zacks Investment Research‘s target price suggests a potential upside of 10.92% from the stock’s current price. According […]